NeuroSpectrum Insights IPOs After FDA Nod for Autism MRI Software

TL;DR

**NeuroSpectrum Insights is a high-risk, high-reward bet on an FDA-cleared autism diagnostic software, but its success hinges entirely on market adoption and reimbursement in a competitive healthcare landscape.**

AI Summary

NeuroSpectrum Insights, Inc. (NSI) is a medical device company focused on commercializing its patented software, GyriCalc, for diagnosing neurological and neurodevelopmental disorders. The company's initial product, GyriCalc, received FDA marketing clearance in July 2025 (K250686) and is designed to assist in autism diagnosis by analyzing MRI images for structural markers. NSI plans to launch GyriCalc in the U.S. and Canada in Q4 2025, targeting an estimated 127,000 new annual autism cases across both countries. The company currently generates no revenue and incurred net losses of approximately $788,000 in 2023, $2,649,000 in 2024, and $851,000 in the first two quarters of 2025, resulting in accumulated deficits of $5,306,348 by December 31, 2024, and $6,157,620 by June 30, 2025. Key risks include reliance on successful market penetration in the U.S. and Canada, securing reimbursement in Canada, and the absence of a public market for its common stock prior to this offering. NSI plans to expand its algorithms to other conditions like dyslexia and ADHD in late 2026.

Why It Matters

This S-1/A filing signals NeuroSpectrum Insights' imminent public debut, offering investors a chance to back a medical device company with FDA-cleared technology in the autism diagnostic space. For patients and clinicians, GyriCalc promises a more objective and potentially faster diagnostic tool, addressing the current subjective methods that can take weeks or months. The company's strategy to target 127,000 new annual autism cases in the U.S. and Canada highlights a significant market opportunity, but also faces competition from established diagnostic protocols and the challenge of securing reimbursement in Canada's publicly funded healthcare system. Employees stand to benefit from the growth potential of a newly public company, while the broader market will watch how this new diagnostic approach impacts the neurodevelopmental disorder landscape.

Risk Assessment

Risk Level: high — The company currently generates no revenue and has accumulated deficits of $6,157,620 as of June 30, 2025, indicating significant financial instability. Furthermore, the filing explicitly states, 'Investing in our Common Stock involves a high degree of risk' and highlights the absence of a public market for its common stock prior to this offering, making valuation and liquidity uncertain.

Analyst Insight

Investors should approach NeuroSpectrum Insights with extreme caution, recognizing it as a speculative investment in an early-stage company with no revenue. Await further financial disclosures post-IPO and monitor market adoption rates of GyriCalc in both the U.S. and Canada before considering a position.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $788,000 — Net loss (Incurred during 2023)
• $2,649,000 — Net loss (Incurred during 2024)
• $851,000 — Net loss (Incurred during the first two quarters of 2025)
• $5,306,348 — Accumulated deficit (As of December 31, 2024)
• $6,157,620 — Accumulated deficit (As of June 30, 2025)
• 94% — Autism identification rate (Achieved by GyriCalc algorithm in clinical study)
• 1 in 31 — Autism prevalence (Estimated in U.S. children by CDC)
• 1 in 50 — Autism prevalence (Reported in Canadian children by McMaster University)
• 127,000 — New annual autism cases (Projected in U.S. and Canada combined)
• 8% — Underwriter warrants (Percentage of shares offered to be purchased by underwriters)

Key Players & Entities

• NeuroSpectrum Insights, Inc. (company) — Registrant and medical device company
• Andrew Stewart (person) — Chief Executive Officer of NeuroSpectrum Insights, Inc.
• Joseph M. Lucosky (person) — Esq. at Lucosky Brookman LLP
• Lawrence Metelitsa (person) — Esq. at Lucosky Brookman LLP
• Fang Liu (person) — Esq. at VCL Law LLP
• Damon D. Testaverde (person) — Shareholder of NeuroSpectrum Insights, Inc. and owner of Network 1 Financial Securities Inc.
• Network 1 Financial Securities Inc. (company) — Sole book-running manager and representative of the underwriters
• University of Louisville (company) — Licensor of GyriCalc technology
• FDA (regulator) — Granted marketing clearance for GyriCalc in July 2025
• NYSE (regulator) — Intended listing exchange for common stock

FAQ

Risk Factors

• Market Adoption and Commercialization Risk [high — market]: NSI's success hinges on the successful commercialization of GyriCalc in the U.S. and Canada, targeting an estimated 127,000 new annual autism cases. Failure to achieve significant market penetration or adoption by healthcare providers could severely impact revenue generation.
• Lack of Profitability and Accumulated Deficit [high — financial]: The company has incurred substantial net losses, totaling $788,000 in 2023, $2,649,000 in 2024, and $851,000 in the first two quarters of 2025. This has resulted in an accumulated deficit of $6,157,620 as of June 30, 2025, indicating a significant need for future funding and a long path to profitability.
• Reimbursement Risk in Canada [high — regulatory]: Securing reimbursement for GyriCalc in Canada is a critical step for market access and revenue generation. Without established reimbursement pathways, adoption and sales in the Canadian market may be significantly hindered.
• Dependence on Specific Target Market [medium — market]: The company's initial focus is solely on diagnosing neurological and neurodevelopmental disorders, specifically autism. While expansion to dyslexia and ADHD is planned for late 2026, the current business model is heavily reliant on the success within the autism diagnosis market.
• Absence of Public Market for Stock [medium — financial]: Prior to this offering, there has been no public market for NSI's common stock. This lack of established trading history and investor base presents uncertainty regarding future stock liquidity and valuation.
• Reliance on Patented Technology [medium — operational]: NSI's core asset is its patented GyriCalc software. Any challenges to the patent's validity, infringement claims, or failure to maintain its proprietary advantage could significantly disrupt the business.

Industry Context

The medical device market for neurological diagnostics is rapidly evolving, driven by advancements in imaging technology and AI-powered analytics. Companies are increasingly focusing on early detection and personalized treatment approaches for disorders like autism, ADHD, and dyslexia. NSI operates in a niche within this market, aiming to leverage its proprietary software for more accurate and efficient diagnosis.

Regulatory Implications

NSI has obtained FDA marketing clearance for GyriCalc, a significant regulatory hurdle cleared for the U.S. market. However, securing reimbursement in Canada presents a separate, crucial regulatory and administrative challenge that will impact market access and revenue realization.

What Investors Should Do

1. Monitor U.S. and Canadian market penetration and sales figures post-launch.
2. Track progress on securing Canadian reimbursement.
3. Evaluate the company's ability to manage cash burn and secure future funding.
4. Assess the timeline and execution risk for expanding algorithms to dyslexia and ADHD.

Key Dates

• 2025-07-01: FDA Marketing Clearance for GyriCalc (K250686) — This is a critical milestone, validating the technology and allowing for commercialization in the U.S. market.
• 2025-10-01: Planned Launch of GyriCalc in U.S. and Canada — Marks the beginning of revenue generation potential for the company.
• 2026-12-01: Planned Expansion of Algorithms to Dyslexia and ADHD — Indicates future growth strategy and diversification beyond autism diagnosis.

Glossary

GyriCalc

NSI's patented software designed to analyze MRI images for structural markers to aid in the diagnosis of neurological and neurodevelopmental disorders. (This is the company's core product and the primary driver of its current business strategy and future revenue.)

FDA Marketing Clearance

Approval from the U.S. Food and Drug Administration allowing a medical device to be legally marketed and sold in the United States. (Essential for NSI to begin commercializing GyriCalc in its primary target market.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, representing the excess of expenses over revenues. (Highlights NSI's current lack of profitability and its reliance on external funding to cover operational costs.)

Reimbursement

The process by which healthcare providers receive payment for services rendered, typically from insurance companies or government programs. (Crucial for NSI's revenue model, especially in Canada, as it determines the financial viability of using GyriCalc for patients.)

Year-Over-Year Comparison

As this is an S-1/A filing, it represents an initial public offering registration. Therefore, direct year-over-year comparisons of financial metrics like revenue growth or margin changes are not applicable. The filing details significant net losses ($788,000 in 2023, $2,649,000 in 2024) and an increasing accumulated deficit ($6,157,620 as of June 30, 2025), highlighting the pre-revenue stage of the company. New risks introduced include the dependence on successful market penetration and securing reimbursement in Canada, alongside the absence of a public market for its stock.

Key Financial Figures

• $0.00001 — ing of shares of common stock par value $0.00001 per share (the “Common Stock&#x2
• $788,000 — we incurred net losses of approximately $788,000, $2,649,000 and $851,000, respectively,
• $2,649,000 — d net losses of approximately $788,000, $2,649,000 and $851,000, respectively, due to pers
• $851,000 — approximately $788,000, $2,649,000 and $851,000, respectively, due to personnel and pro
• $5,306,348 — 0, 2025 we show accumulated deficits of $5,306,348 and $6,157,620, respectively. Our Prod
• $6,157,620 — accumulated deficits of $5,306,348 and $6,157,620, respectively. Our Product Targeted at
• $1,000 — brain MRI scan in the United States is ~$1,000 2 Our business plan introduces GyriCa
• $7,500 — om $1,000 for straight forward cases to $7,500 or more for complex, difficult to diagn
• $1,500 — oviders). At a projected list price of $1,500 U.S. per patient we estimate a 5 -Year

Filing Documents

• ea0212248-04.htm (S-1/A) — 4950KB
• ea021224804ex23-1_neuro.htm (EX-23.1) — 5KB
• theader_001.jpg (GRAPHIC) — 166KB
• theader_002.jpg (GRAPHIC) — 130KB
• ex23-1_001.jpg (GRAPHIC) — 16KB
• ex23-1_002.jpg (GRAPHIC) — 13KB
• 0001213900-25-091162.txt ( ) — 5402KB

RISK FACTORS

RISK FACTORS   14 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY AND MARKET DATA   43

USE OF PROCEEDS

USE OF PROCEEDS   45 DIVIDEND POLICY   46 CAPITALIZATION   47

DILUTION

DILUTION   48

BUSINESS

BUSINESS   56 MANAGEMENT   67 EXECUTIVE AND DIRECTOR COMPENSATION   72

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT   74 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS   75

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK   77

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING   79 SHARES ELIGIBLE FOR FUTURE SALE   81

UNDERWRITING

UNDERWRITING   83 LEGAL MATTERS   87 EXPERTS   87 WHERE YOU CAN FIND MORE INFORMATION   87 INDEX TO FINANCIAL STATEMENTS   F-1 We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the Shares offered hereby, but only under the circumstances and in the jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our Shares, Common Stock or Warrants. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus or any applicable free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus and any applicable free writing prospectus must inform themselves, and observe any restrictions relating to, the offering of the Shares and the distribution of this prospectus outside the United States. Through and including [*] , 2025 (25 days after the date of this prospectus), all dealers that buy, sell or trade our Common Stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of deale

View Full Filing

View this S-1/A filing on SEC EDGAR